IE20100196A1 - A glass ceramical biomaterial - Google Patents
A glass ceramical biomaterialInfo
- Publication number
- IE20100196A1 IE20100196A1 IE20100196A IE20100196A IE20100196A1 IE 20100196 A1 IE20100196 A1 IE 20100196A1 IE 20100196 A IE20100196 A IE 20100196A IE 20100196 A IE20100196 A IE 20100196A IE 20100196 A1 IE20100196 A1 IE 20100196A1
- Authority
- IE
- Ireland
- Prior art keywords
- biomaterial
- crystalline
- silicate
- strontium
- molar percentage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/10—Ceramics or glasses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C10/00—Devitrified glass ceramics, i.e. glass ceramics having a crystalline phase dispersed in a glassy phase and constituting at least 50% by weight of the total composition
- C03C10/0009—Devitrified glass ceramics, i.e. glass ceramics having a crystalline phase dispersed in a glassy phase and constituting at least 50% by weight of the total composition containing silica as main constituent
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C3/00—Glass compositions
- C03C3/04—Glass compositions containing silica
- C03C3/062—Glass compositions containing silica with less than 40% silica by weight
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C3/00—Glass compositions
- C03C3/04—Glass compositions containing silica
- C03C3/076—Glass compositions containing silica with 40% to 90% silica, by weight
- C03C3/078—Glass compositions containing silica with 40% to 90% silica, by weight containing an oxide of a divalent metal, e.g. an oxide of zinc
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C4/00—Compositions for glass with special properties
- C03C4/0007—Compositions for glass with special properties for biologically-compatible glass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Geochemistry & Mineralogy (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dispersion Chemistry (AREA)
- Ceramic Engineering (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Glass Compositions (AREA)
Abstract
A glass ceramic biomaterial (1) comprises SrO, ZnO, CaO, SiO2 and Na2O. The biomaterial (1) has a crystalline atomic structure. The biomaterial (1) is provided in the form of a porous foam. the biomaterial (1) with the crystalline atomic structure is degradable for release of bioactive Sr2+ ions and for release of bioactive Zn2+ ions. The Sr2+ ions may assist with bone regeneration, and the Zn2+ ions may provide an anti-bacterial function. <Figure 1>
Description
This invention relates to a glass ceramic biomaterial.
Statements of Invention
ΟΡΪΛ at PtiSUC WSPECTHW «
hit 0./3+). ...
C&& C· Ι&Ι#Ο.
According to the invention there is provided a glass ceramic biomaterial having a crystalline atomic structure, at least part of the biomaterial being degradable for release of bioactive ions.
The structure of the biomaterial enables the biomaterial to be employed in load bearing applications without an additional binding agent and/or cement and/or binding gel being required. The biomaterial may also be employed in non load bearing applications.
By releasing bioactive ions, the biomaterial may assist in promoting a therapeutic response in a body tissue and/or in a body bone and/or in a body part.
In one embodiment of the invention the biomaterial comprises strontium (Sr). Strontium is particularly effective in promoting bone regeneration in bone tissue. Preferably the biomaterial comprises SrO. Ideally the molar percentage of SrO is between 10% and 40%. Most preferably the biomaterial is degradable for release of Sr21 ions.
In another embodiment the biomaterial comprises zinc (Zn). Zinc is particularly effective as an anti-bacterial agent to minimise infection. Preferably the biomaterial
PO55EE /Ε 10 0 196 comprises ZnO. Ideally the molar percentage of ZnO is between 0.1% and 30%. Most preferably the biomaterial is degradable for release of Zn2+ ions.
En one case the biomaterial comprises calcium (Ca). Preferably the biomaterial 5 comprises CaO. Ideally the molar percentage of CaO is between 0.1% and 20%.
In another case the biomaterial comprises silicon (Si). Preferably the biomaterial comprises S1O2. Ideally the molar percentage of S1O2 is between 33% and 60%.
In one embodiment the biomaterial comprises sodium (Na). Preferably the biomaterial comprises Na2O. Ideally the molar percentage of NajO is between 0.1% and 40%.
The biomaterial may comprise crystalline strontium zinc silicate. The biomaterial may comprise crystalline sodium calcium silicate. In one case the biomaterial comprises a blend of crystalline strontium zinc silicate and crystalline sodium calcium silicate.
The biomaterial may comprise crystalline sodium zinc silicate. The biomaterial may comprise crystalline calcium silicate. In one case the biomaterial comprises a blend of crystalline sodium zinc silicate and crystalline calcium silicate.
The biomaterial may comprise crystalline strontium silicate. The biomaterial may comprise crystalline sodium silicate. In one case biomaterial comprises a blend of crystalline calcium silicate and crystalline strontium silicate and crystalline sodium silicate. In another case the biomaterial comprises a blend of crystalline strontium zinc silicate and crystalline strontium silicate and crystalline sodium zinc silicate. In a further case the biomaterial comprises a blend of crystalline strontium silicate and crystalline sodium zinc silicate.
IE 100196
P055IE
In another embodiment the crystallisation temperature is between 400° C and 900° C. Preferably the crystallisation temperature is between 500° C and 800° C.
In one case the biomaterial comprises a foam. Preferably at least part of the 5 biomaterial is porous. The porous biomaterial may assist in promoting tissue ingrowth.
The invention also provides in another aspect the use of a glass ceramic biomaterial of die invention for prophylactic treatment at a bone tissue fracture site.
In a further aspect of the invention there is provided the use of a glass ceramic biomaterial of the invention as a bone tissue autograft extender.
The invention also provides in another aspect the use of a glass ceramic biomaterial of the invention as a radiopacifier and/or as a coating for a heart tissue.
Brief Description of the Drawings
The invention will be more clearly understood from the following description of some embodiments thereof, given by way of example only, with reference to the accompanying drawings, in which:
Fig. 1 is an X-ray tomography image of a glass ceramic biomaterial according to the invention,
Fig. 2 is a graph illustrating the phase transformation of the glass ceramic biomaterial of Fig. 1,
IE 10 0 19 6
PO55IE
Fig. 3 is an X-ray tomography image of four cross sections of the glass ceramic biomaterial of Fig. I,
Figs. 3(a) to 3(d) are graphs illustrating the phase transformation of four other glass 5 ceramic biomaterials according to the invention,
Fig. 4 is a graph illustrating ion release for the glass ceramic biomaterial of Fig. 1 and three of the glass ceramic biomaterials of Figs. 3(a) to 3(d), and
Fig. 5 is an image of the glass ceramic biomaterial of Fig. 1 with a precipitate apatite bioactive coating.
Detailed Description
Referring to the drawings, and initially to Figs. 1 to 3 thereof, there is illustrated a glass ceramic biomaterial 1 according to the invention.
The biomaterial 1 comprises strontium (Sr), zinc (Zn), calcium (Ca), silicon (Si), and sodium (Na). In particular the biomaterial 1 comprises SrO, ZnO, CaO, S1O2 and Na2O. In this case the biomaterial 1 consists of SrO, ZnO, CaO, S1O2 and Na2O and is free of any further binding agents and/or cements and/or binding gels. The molar percentage of SrO may be between 10% and 40%. The molar percentage of ZnO may be between 0.1% and 30%. The molar percentage of CaO may be between 0.1% and 20%. The molar percentage of S1O2 may be between 33% and 60%. The molar percentage of Na2O may be between 0.1% and 40%. In this case the molar percentage of SrO is 20%, the molar percentage of ZnO is 20%, the molar percentage of CaO is 10%, the molar percentage of S1O2 is 40%, and the molar percentage of Na2O is 10%.
/f 100 1 9β
P0S5E
The biomaterial 1 has a crystalline atomic structure. In this case the biomaterial 1 comprises a blend of crystalline strontium zinc silicate and crystalline sodium calcium silicate. The biomaterial 1 is provided in the form of a porous foam.
The crystallisation temperature of the biomaterial 1 may be between 400° C and 900° C, and preferably is between 500° C and 800° C. In this case the crystallisation temperature ofthe biomaterial 1 is 713° C.
Fig. 2 illustrates the phase transformation of the basic glass composition into the 10 biomaterial 1 at the first crystallization point (Tpi). During processing, the basic glass composition converts from an amorphous glass into the blend of crystalline strontium zinc silicate and crystalline sodium calcium silicate at the first crystallization point (Tpi), as illustrated in Fig. 2. This conversion radically alters the structural characteristics and properties of the biomaterial 1 in comparison to the basic glass composition.
Surprisingly the biomaterial 1 with the crystalline atomic structure is degradable for release of bioactive ions. In this case the biomaterial 1 is degradable for release of Sr2+ ions and for release of Zn2+ ions. Fig. 4 illustrates the Zn2+ ion release at 7 days and at 30 days maturation under Ph3 and Ph7. It would have been expected that the processing of the basic glass composition would have resulted in a stable inert glass ceramic, and it would have been expected that the resulting atomic structure would not have enabled any ion release. Contrary to what would have been conventionally expected, it has been found unexpectedly that the processing of the basic glass composition results in the biomaterial 1 with the crystalline atomic structure which provides for degradation and release of constituent ions, as illustrated in Fig. 4.
The glass based biomaterial 1 releases ions which may lead to a therapeutic response for example in a bone prosthesis in a human body. The Sr2* ions may assist with bone regeneration, and the Zn2+ ions may provide an anti-bacterial function. The
IE 100 7 96
PO55IE biomaterial 1 offers the controlled release of ions which are known to inhibit bacterial colonisation of implants and synergistically release ions which promote osteoblastic bone formation at the expense of osteoclastic bone resorption. The biomaterial 1 offers a synergy of antibacterial and regenerative ion release. In the biomaterial 1, the Zn2+ ions are released at levels appropriate to inhibit infection in vivo.
The bioactive glass of the invention comprises Calcium-Strontium-Zinc-Silicate.
The glass releases controlled amounts of therapeutic Zn2+ and Sri+ ions when placed in normal and extreme physiological conditions. The bioactive glass is suited to utilize as a bone replacement material. The level of Zn2+ and Sr2-1· ions released from the bioactive glass material achieve clinical benefits and therapeutic effects including bone formation in the range of 2.45 to 6.5 parts per million (ppm), and antibacterial efficacy of 3-7 ppm respectively.
The crystalline atomic structure of the biomaterial 1 is a function of the composition of the biomaterial 1, the processing temperature to produce the biomaterial 1, and the length of time which the biomaterial 1 is processed at this temperature. The invention provides a glass ceramics construct with a synergistic composition of Sr2+ and Zn2+ in which the crystalline atomic structure may be chosen to alter the material properties of the biomaterial 1.
The biomaterial 1 is provided in the form of a solid, load-bearing structure. No further binding agents and/or cements and/or binding gels are required with the 25 biomaterial 1. The biomaterial 1 has the ability to bear loads normal to physiological loading in the skeleton. The biomaterial 1 may also be deployed as a non loadbearing element
Fig. 1 illustrates an X-ray tomography (XRT) image of the foam biomaterial 1. The porous nature of the biomaterial 1 facilitates tissue in-growth.
IE 10 0 1 96
The glass ceramic biomaterial 1 may be deployed as a fully reticulated foam, a bulk biomaterial or a coating. The biomaferial 1 is suitable for the following fields of use: load-bearing and non load-bearing dental, craniofacial, maxillofacial and/or orthopaedic applications.
infection may be an ongoing clinical concern, both immediate to introduction of biomaterials in the body and for the long term viability of the in vivo construct. The biomaterial 1 offers an antibacterial solution to reduce infection at the post-operative stage, whilst also offering full porosity for bone in-growth, and load bearing capabilities for increased scope of applications. In respect of patients who suffer from metabolic hone diseases such as osteoporosis, the invention provides for controlled release of therapeutic agents, such as Sr2+, from a load bearing construct either foam, bulk or coating. The inclusion of Sr2* in synergy with Zn2+ also offers significant advantages in bone regeneration as a function of controlled ion release to mediate specific regenerative responses in bone tissue in a material capable of forming a direct bond with bone while retaining bone bonding capabilities, as illustrated in Fig. 5. Fig. 5 illustrates a surface image of the biomaterial 1 immerged in simulated body fluid (SBF) for 7 days showing a precipitate apatite bioactive coating.
The biomaterial 1 has numerous advantages from a material and surgical applications standpoint, for example the capability to release ions, applicability to non loadbearing applications as well as applicability to load-bearing applications, capability of being deployed as a reticulated foam, and being a fully crystalline material,
The biomaterial 1 may be employed in a variety of applications, for example for controlled drug delivery, and/or for drug delivery in combination with a hydrogel, and/or for stem cell tissue engineering, and/or as a component in a toothpaste for sensitivity control, and/or as a component in a bone cement for improved radiopacity,
Ρ055ΒΕ
IE 10 0 19 6
P055IL· and/or as a component in a bone cement for improved biocompatibility and/or antibacterial efficacy, and/or as a component of a composite biomaterial for tissue engineering, and/or as a coating on a medical device.
The biomaterial 1 may be used for prophylactic treatment at a bone tissue fracture site, such as the neck of a femur or a vertebra. The biomaterial 1 may be used as a bone tissue autograft extender. The biomaterial 1 may be used as a radiopacifier and/or as a coating for a heart tissue.
The biomaterial 1 may be provided in a variety of shapes, for example as a rod, and/or a plate, and/or a prosthetic bone shape.
Fig. 3 illustrates the XRT montage of the biomaterial 1 of the invention illustrating the interconnected pore structure through multiple cross sections of the biomaterial 1.
In a second embodiment of the invention, the biomaterial comprises SrO, ZnO, CaO, S1O2 and Na2O. In this case the molar percentage of SrO is 20%, the molar percentage of ZnO is 10%, the molar percentage of CaO is 10%, the molar percentage of S1O2 is 40%, and the molar percentage of Na2O is 20%.
In this case the biomaterial comprises a blend of crystalline sodium zinc silicate and crystalline calcium silicate.
In this case the crystallisation temperature of the biomaterial is 577° C.
In a third embodiment of the invention, the biomaterial comprises SrO, CaO, S1O2 and Na2O. In this case the molar percentage of SrO is 20%, the molar percentage of ZnO is 0%, the molar percentage of CaO is 10%, the molar percentage of S1O2 is 40%, and the molar percentage of Na2O is 30%.
IE 10 0 19 6
PO55E
In this case the biomaterial comprises a blend of crystalline calcium silicate and crystalline strontium silicate and ciystalline sodium silicate.
In this case the crystallisation temperature of the biomaterial is 525° C.
In a fourth embodiment of the invention, the biomaterial comprises SrO, ZnO, SiO? and Na2O. In this case the molar percentage of SrO is 30%, the molar percentage of ZnO is 20%, the molar percentage of CaO is 0%, the molar percentage of S1O2 is 40%, and the molar percentage of Na?O is 10%.
In this case the biomaterial comprises a blend of crystalline strontium zinc silicate and crystalline strontium silicate and crystalline sodium zinc silicate.
In this case the crystallisation temperature of the biomaterial is 668° C.
In a fifth embodiment of the invention, the biomaterial comprises SrO, ZnO, SiO? and Na?O. In this case the molar percentage of SrO is 30%, the molar percentage of ZnO is 10%, the molar percentage of CaO is 0%, the molar percentage of SiO2 is 40%, and the molar percentage of Na2O is 20%.
In this case the biomaterial comprises a blend of crystalline strontium silicate and crystalline sodium zinc silicate.
In this case the crystallisation temperature of the biomaterial is 567° C.
The following table lists the glass compositions in mol. fractions.
Glass designation SiO 2 ZnO CaO SrO Na2O First embodiment 0.4 0.2 0.1 0.2 0.1
fc 10 0 7 96 ίο
P055IE
Second embodiment 0.4 0.1 0.1 0.2 0.2 Third embodiment 0.4 0 0.1 0.2 0.3 Fourth embodiment 0.4 0.2 0 0.3 0.1 Fifth embodiment 0.4 0.1 0 0.3 0.2
The following table lists the glass compositions with the crystalline compounds formed at Tpi. Tpi is the first crystallization point, which is the temperature at which the glass converts fully to a crystalline ceramic.
Glass-Ceramic Designate TPi(°C) Crystalline Compound Formed at Tpi First embodiment 713 Strontium Zinc Silicate Sodium Calcium Silicate Second embodiment 577 Sodium Zinc Silicate Calcium Silicate Third embodiment 525 Calcium Silicate Strontium Silicate Sodium Silicate Fourth embodiment 668 Strontium Zinc Silicate Strontium Silicate Sodium Zinc Silicate Fifth embodiment 567 Strontium Silicate Sodium Zinc Silicate
Figs. 3(a) to 3(d) illustrate an XRD trace for each biomaterial 2, 3,4,5 after processing at the respective Tpl.
fe 100196
P055IE
The invention is not limited to the embodiments hereinbefore described, with reference to the accompanying drawings, which may be varied in construction and detail.
Claims (34)
1. A glass ceramic biomaterial having a crystalline atomic structure, at least part of the biomaterial being degradable for release of bioactive ions.
2. A biomaterial as claimed in claim 1 wherein the biomaterial comprises strontium (Sr).
3. A biomaterial as claimed in claim 2 wherein the biomaterial comprises SrO.
4. A biomaterial as claimed in claim 3 wherein the molar percentage of SrO is between 10% and 40%.
5. A biomaterial as claimed in any of claims 2 to 4 wherein the biomaterial is 15 degradable for release of Sr 2 * ions.
6. A biomaterial as claimed in any of claims 1 to 5 wherein the biomaterial comprises zinc (Zn). 20
7. A biomaterial as claimed in claim 6 wherein the biomaterial comprises ZnO.
8. A biomaterial as claimed in claim 7 wherein the molar percentage of ZnO is between 0.1% and 30%. 25
9. A biomaterial as claimed in any of claims 6 to 8 wherein the biomaterial is degradable for release of Zn 2 * ions.
10. A biomaterial as claimed in any of claims 1 to 9 wherein the biomaterial comprises calcium (Ca). ΙΕ ί Ο Ο ί 9 g PO55E
11. A biomaterial as claimed in claim 10 wherein the biomaterial comprises CaO.
12. A biomaterial as claimed in claim 11 wherein the molar percentage of CaO is between 0.1% and 20%.
13. A biomaterial as claimed in any of claims 1 to 12 wherein the biomaterial comprises silicon (Si).
14. A biomaterial as claimed in claim 13 wherein the biomaterial comprises S1O2.
15. A biomaterial as claimed in claim 14 wherein the molar percentage of S1O2 is between 33% and 60%.
16. A biomaterial as claimed in any of claims 1 to 15 wherein the biomaterial 15 comprises sodium (Na).
17. A biomaterial as claimed in claim 16 wherein the biomaterial comprises Na 2 O. 20
18. A biomaterial as claimed in claim 17 wherein the molar percentage of Na2<) is between 0.1% and 40%.
19. A biomaterial as claimed in any of claims 1 to 18 wherein the biomaterial comprises crystalline strontium zinc silicate.
20. A biomaterial as claimed in any of claims 1 to 19 wherein the biomaterial comprises crystalline sodium calcium silicate. IE 100196 P055IE
21. A biomaterial as claimed in claims 19 and 20 wherein the biomaterial comprises a blend of crystalline strontium zinc silicate and crystalline sodium calcium silicate. 5
22. A biomaterial as claimed in any of claims 1 to 21 wherein the biomaterial comprises crystalline sodium zinc silicate.
23. A biomaterial as claimed in any of claims 1 to 22 wherein the biomaterial comprises crystalline calcium silicate.
24. A biomaterial as claimed in claims 22 and 23 wherein the biomaterial comprises a blend of crystalline sodium zinc silicate and crystalline calcium silicate. 15 25. A biomaterial as claimed in any of claims 1 to 24 wherein the biomaterial comprises crystalline strontium silicate. 26. A biomaterial as claimed in any of claims 1 to 25 wherein tiie biomaterial comprises crystalline sodium silicate. 27. A biomaterial as claimed in claims 23,25 and 26 wherein the biomaterial comprises a blend of crystalline calcium silicate and crystalline strontium silicate and crystalline sodium silicate.
25. 28. A biomaterial as claimed in claims 19,25 and 22 wherein the biomaterial comprises a blend of crystalline strontium zinc silicate and crystalline strontium silicate and crystalline sodium zinc silicate. IE 10 0 7 9 6 PO55IE
26. 29. A biomaterial as claimed in claims 25 and 22 wherein the biomaterial comprises a blend of ciystalline strontium silicate and crystalline sodium zinc silicate. 5
27. 30. A biomaterial as claimed in any of claims 1 to 29 wherein the crystallisation temperature is between 400° C and 900° C.
28. 31. A biomaterial as claimed in claim 30 wherein the crystallisation temperature is between 500° C and 800° C.
29. 32. A biomaterial as claimed in any of claims 1 to 31 wherein the biomaterial comprises a foam.
30. 33. A biomaterial as claimed in any of claims 1 to 32 wherein at least part of the 15 biomaterial is porous.
31. 34. A glass ceramic biomaterial substantially as hereinbefore described with reference to the accompanying drawings. 20
32. 35. Use of a glass ceramic biomaterial as claimed in any of claims 1 to 34 for prophylactic treatment at a bone tissue fracture site.
33. 36. Use of a glass ceramic biomaterial as claimed in any of claims 1 to 34 as a bone tissue autograft extender.
34. 37. Use of a glass ceramic biomaterial as claimed in any of claims 1 to 34 as a radiopacifier and/or as a coating for a heart tissue.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IE20100196A IE20100196A1 (en) | 2010-04-01 | 2010-04-01 | A glass ceramical biomaterial |
| PCT/EP2011/055039 WO2011121087A1 (en) | 2010-04-01 | 2011-03-31 | A glass ceramic biomaterial |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IE20100196A IE20100196A1 (en) | 2010-04-01 | 2010-04-01 | A glass ceramical biomaterial |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IE20100196A1 true IE20100196A1 (en) | 2012-02-29 |
Family
ID=44146846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE20100196A IE20100196A1 (en) | 2010-04-01 | 2010-04-01 | A glass ceramical biomaterial |
Country Status (2)
| Country | Link |
|---|---|
| IE (1) | IE20100196A1 (en) |
| WO (1) | WO2011121087A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102380127A (en) * | 2011-11-09 | 2012-03-21 | 同济大学 | Preparation method and application of antibacterial glass coating of antibacterial bone fracture plate |
| US20140050765A1 (en) * | 2012-08-14 | 2014-02-20 | Bio2 Technologies, Inc. | Devices and Methods for Tissue Engineering |
| JP6297065B2 (en) * | 2013-01-31 | 2018-03-20 | ディーナ カツィール | Low fluorescent equipment |
| WO2018014120A1 (en) | 2016-07-20 | 2018-01-25 | Mark Robert Towler | Glasses, cements and uses thereof |
| CN112441742A (en) * | 2019-08-30 | 2021-03-05 | 江苏启灏医疗科技有限公司 | Bioactive glass, nasal cavity stent composite material and application thereof |
| CN114137008B (en) * | 2021-11-30 | 2024-03-01 | 重庆登康口腔护理用品股份有限公司 | Method for detecting bioactive ceramic active ingredients in toothpaste |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004026432A1 (en) * | 2004-05-29 | 2005-12-22 | Schott Ag | Glass compositions as antimicrobial additive for dental materials and their use |
| US20080208340A1 (en) * | 2007-02-26 | 2008-08-28 | Daniel Boyd | Synthetic bone graft |
| WO2010003191A1 (en) * | 2008-07-10 | 2010-01-14 | The University Of Sydney | Biocompatible material and uses thereof |
-
2010
- 2010-04-01 IE IE20100196A patent/IE20100196A1/en not_active Application Discontinuation
-
2011
- 2011-03-31 WO PCT/EP2011/055039 patent/WO2011121087A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011121087A1 (en) | 2011-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Canillas et al. | Calcium phosphates for biomedical applications | |
| Pina et al. | Bioceramics for osteochondral tissue engineering and regeneration | |
| US8778378B2 (en) | Bioactive antibacterial bone graft materials | |
| Kao et al. | A review of bone substitutes | |
| Manjubala et al. | Bioactivity and osseointegration study of calcium phosphate ceramic of different chemical composition | |
| JP6072013B2 (en) | Biocompatible materials and their use | |
| US20130202670A1 (en) | Bioactive antibacterial bone graft materials containing silver | |
| Rahaman | Bioactive ceramics and glasses for tissue engineering | |
| US9913931B2 (en) | Cement-forming compositions, monetite cements, implants and methods for correcting bone defects | |
| IE20100196A1 (en) | A glass ceramical biomaterial | |
| EP2080528B1 (en) | Preparation for regeneration of postoperative and post-traumatic bone defects | |
| Demirel et al. | Effect of strontium-containing compounds on bone grafts | |
| Pina et al. | Ceramic biomaterials for tissue engineering | |
| Jones et al. | Ceramics, glasses, and glass-ceramics: Basic principles | |
| Ramesh et al. | Calcium-based ceramic biomaterials | |
| Daculsi et al. | The micro macroporous biphasic calcium phosphate concept for bone reconstruction and tissue engineering | |
| US8221504B2 (en) | Coating an implant for increased bone in-growth | |
| Layrolle et al. | Physicochemistry of apatite and its related calcium phosphates | |
| Padilla et al. | Novel nanostructured Zn-substituted monetite based biomaterial for bone regeneration | |
| Döbelin et al. | Synthetic calcium phosphate ceramics for treatment of bone fractures | |
| ES2373137B2 (en) | CEMENT OF CALCIUM-CALCIUM SILICATE PHOSPHATE FOR BIOMEDICAL APPLICATIONS. | |
| Lun et al. | Limitations and modifications in the clinical application of calcium sulfate | |
| Fernandez et al. | Biointegration of bone graft substiutes from osteointegration to osteotranduction | |
| Bakheet et al. | First principles study of the physical properties of pure and doped calcium phosphate biomaterial for tissue engineering | |
| Jirofti et al. | Review on Hydroxyapatite-Based Coatings as Antibiotic Delivery System on Bone Graft Substitution for Controlling Infection in Orthopedic Surgery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC9A | Application refused sect. 31(1) |